GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.

Slides:



Advertisements
Similar presentations
PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
Advertisements

Malta Council for Science and Technology Seventh Framework Programme (FP7) 15 July, 2008 Anthea Frendo FP7 National Contact Point.
Research and Innovation Research and Innovation Enabling & Industrial Technologies in Horizon 2020 Enabling & Industrial Technologies in Horizon 2020 Research.
Prof Desmond Sheridan ESC mission To improve the quality of life of the European population by reducing the impact of cardiovascular disease.
1 EFPC congress Gőteborg 2012 Interprofessional Education for Primary Care Professionals L. van Amsterdam.
EU RTD + FP Cancer Treatment: A priority for patients in Europe 7 th European Health Forum Bad Gastein 7 October, 2004 Cornelius Schmaltz MD European.
Combating major diseases Gender aspects in research Gender aspects in research have a particular relevance to this theme as risk factors, biological mechanisms,
G aps, challenges and opportunities Theo Verheij University Medical Center Utrecht Lower Respiratory Tract Infections in Primary Care.
TRAINING FOR ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN HOSPITALS JUNE 2014.
Irish Health Research: Collaboration and Partnership HSE Regional Library & Information Health Research Seminar Dr. Steevens’ Hospital 11th February 2011.
Knowledge Translation: A View from a National Policy Perspective KU-02 Conference Oxford, England July 2, 2002.
Clinical Pharmacy Basma Y. Kentab MSc..
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Hans Wolf-Watz, professor, UCMR, MIMS, Department of Microbiology, Umeå University, Sweden, Antibiotic resistance a new.
European Health Forum Gastein, Bad Hofgastein, Austria, September 2002 Towards the Sixth Framework Programme Parallel Forum V 26 September 2002 Public.
Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.
Achutha Menon Centre for Health Science Studies Sree Chitra Tirunal Institute for Medical Sciences and Technology.
Health Promoting Health Service: Development day.
Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.
Director, DG RTD, Directorate International Cooperation
European Health Forum Gastein, Bad Hofgastein, Austria, September 2002 The Sixth Framework Programme and Policy Support Research – “Priority 8” Parallel.
Rafael Rodriguez, Prof. of Research Fp7 THE CAPACITIES PROGRAMME and its International Cooperation Activities.
GRACE: The First Network of Excellence on Primary Care in Europe Herman Goossens Co-ordinator.
Where to focus? Horizon 2020 'Health, demographic change and wellbeing' Open Info Day -Horizon 2020 'Health, demographic change and wellbeing' Brussels,
Mycoplasma pneumoniae is not an important cause of lower respiratory tract infections in the European GRACE study: a combination of methods is necessary.
For more information, visit : or contact: Summary PROMOVAX is a 3-year EU-funded project.
RTD-B.4 - Regions of Knowledge and Research Potential Regional Dimension of the 7th Framework Programme Regions of Knowledge Objectives and Activities.
A new start for the Lisbon Strategy Knowledge and innovation for growth.
Improving care for people with intellectual disabilities across the life span The ACI Intellectual Disability Network: Maxine Andersson Agency for Clinical.
Ecdc.europa.eu Tommi Asikainen, Tubingen, 22 October 2008 European Centre for Disease Prevention and Control FUTURE DISEASE CHALLENGES IN EUROPE – where.
1 NEST New and emerging science and technology EUROPEAN COMMISSION - 6th Framework programme : Anticipating Scientific and Technological Needs.
EPIDEMIOLOGY DENGUE, MALARIA Priority Areas for Planning Dengue Emergency Response 1. Establish a multisectoral dengue action committee.
September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.
Crosswalk of Public Health Accreditation and the Public Health Code of Ethics Highlighted items relate to the Water Supply case studied discussed in the.
ResearchEuropean Commission FP 6 - Thematic Priority 1 International co-operation.
Clinical trials in Framework programme 7 (FP7) EU Judita Kinkorová 2. Národní konference o doporučených postupech, Olomouc 13. listopadu 2010.
Building the Europe of Knowledge Proposals for the 7 th Research Framework Programme
”There is nothing so practical as a good theory” Management research in the improvement of health services Mats Brommels Medical Management Centre Karolinska.
1 SMEs – a priority for FP6 Barend Verachtert DG Research Unit B3 - Research and SMEs.
Seventh Framework Programme Theme 1 - Health Ph D.Olguta Iordache Health - NCP.
GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.
DETERMINE Working document # 4 'Economic arguments for addressing social determinants of health inequalities' December 2009 Owen Metcalfe & Teresa Lavin.
FP7 /1 EUROPEAN COMMISSION - Research DG – September 2006 Building a Europe of Knowledge Towards the Seventh Framework Programme
The Seventh Framework Programme for Research and Technological Development (FP7) supporting innovation Epp Tohver-Bulavs 07. November 2007, Tallinn.
Poznan 19 April Kwietnia 2005 Poznan FP6 The Next Calls for 2005 Technology Platforms FP7.
EARIP Stakeholder Workshop Models and healthcare systems: transferability of best practice across Europe Dr. Aurélien PEREZ European Commission Health.
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
Alun JONES EU Network Manager European Agency for Safety and Health at Work 6 th Framework Programme on Research.
Joint Action on Addressing Chronic Diseases and Healthy Ageing Across the Life-Cycle (JA-CHRODIS) An Overview Teresa Chavarría National Institute of Health.
EHFG 7 October 2005 – Patient Safety & Research UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European.
Single Competency Framework for Prescribers National Prescribing Centre (2012)
Clinical Research Informatics [CRI]. Informatics, defined generally as the intersection of information and computer science with a health-related discipline,
EARIP- European Asthma Research and Innovation Partnership Dr Samantha Walker (Asthma UK) “Does innovative research for allergy and respiratory disease.
Concepts of Primary health care Ass.Prof:Dr:Essmat Gemaey
Advisory Forum November 28th-29th 2005 HIV, AIDS and Other Sexually Transmitted and Blood Borne Infections Prof Angus Nicoll SNE - HIV & STI Co-ordinator.
Implementing operational research for HIV treatment scale-up in resource-limited settings TB/HIV Research Priorities in Resource-Limited Settings Expert.
The 7th Framework Programme for Research: Strategy of international cooperation activities Robert Burmanjer Head of Unit, “International Scientific Cooperation.
© UEG Presentation by Towards more coordination in health research: a report on the UEG research symposium 16/11/2012 Michael Manns General Assembly.
European network for Health Technology Assessment | JA | EUnetHTA European network for Health Technology Assessment THL Info.
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
6th Framework Programme – Research for Policy - November 2002 The Sixth Framework Programme and Policy Support Research – “Priority 8” “Priority 8” - 6th.
Professor Orla Hardiman HRB Clinician Scientist Innovation Its role in Delivering Better Health Outcomes.
Third Meeting of National Contact Points
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Integrating Genetics & Genomics Education into Nursing Workforce
Musculoskeletal Health in Europe
ISARIC – INTERNATIONAL SEVERE ACUTE RESPIRATORY INFECTION CONSORTIUM
Call topic identification for 2019 call
The International Consortium for Personalised Medicine
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Presentation transcript:

GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven (Lab. Network Support), S. Coenen (PC Network Support), T. Sterckx (Administrator) The overall aim of GRACE is to combat antimicrobial resistance through integrating and strengthening centres of excellence for studying the application of genomics with primary care practitioners, to community-acquired LRTI, which is the leading reason for seeking medical care and consuming antibiotics. GRACE will develop into a “European LRTI Research Centre” to investigate and improve the point-of-care management of community-acquired LRTI. Novel rapid genome based diagnostic tests for the detection of pathogens implicated in community-acquired LRTI. A European repository of specimens and strains linked to a database including microbial and patient information. Risk factors for infection with resistant S. pneumoniae and H. influenzae in patients with community-acquired LRTI. Pneumococcal genes important for virulence and for antibiotic resistance development. Optimal pneumococcal treatment and prevention strategy linked to severity of community-acquired LRTI. Human susceptibility genes affecting severe community-acquired LRTI. Potential human target pathways for new immunomodulatory approaches. Potential genetic risk profiles for various presentations and outcomes of community-acquired LRTI in several European populations. Evidence-based definitions of the major community-acquired LRTI. Clinical outcome measures for evaluating interventions. Clinical models to differentiate viral from bacterial infections and identify pneumonia. Clinical models to identify patients at risk for adverse outcomes including severe and prolonged illness. Subgroups of patients with community-acquired LRTI which benefit and which do not from antibiotic treatment. Practice based intervention in reducing inappropriate antibiotic use and resistance in patients with community-acquired LRTI. Cost-effectiveness of the management strategies developed in the observational and intervention studies. A model for the macroeconomic impact of antibiotic resistance and policies to contain resistance. Economic evaluations of molecular diagnostics. Educational packages to inform postgraduate lifelong learning needs of prescribing professionals. AIM LONG TERM IMPACT Establish the principle and practice of linking basic science with clinical care for community-acquired LRTI Enhance the competitiveness of European translational research Link science with education and provide a focus for spreading of excellent practice throughout Europe Cement future international research collaborations linking international experts in primary and secondary care research in community-acquired LRTI Contribute to EC policy developments Strengthen European excellence and achieve a leadership on community-acquired LRTI GRACE will serve as model of how different but relevant disciplines in health care can be integrated and combined and of how the full cycle of translating basic science innovation into clinical care can be achieved efficiently and seamlessly. GRACE will develop into a “European LRTI Research Centre” to investigate and improve the point-of-care management of community- acquired LRTI. CONCLUSION POTENTIAL APPLICATIONS This project is supported through Priority 1 (Life Sciences, Genomics and Biotechnology for Health) of European Union's FP6, Contract number: LSHM-CT Fig. 1: Map of Academic and SME partners participating in GRACE Fig. 2: Map of primary care networks participating in GRACE ABSTRACT GRACE is a Network of Excellence focusing on the complex and controversial field of community- acquired lower respiratory tract infections (LRTI), which is one of the leading reasons for seeking medical care. The promiscuous use of antibiotics to treatment of LRTI accounts for a major part of the community burden of antibiotic use and contributes dramatically to the rising prevalence of resistance among major human pathogens. The overall objective of GRACE is to combat antimicrobial resistance through integrating centres of research excellence and exploiting genomics in the investigation of community-acquired LRTI. Microbial and human genomics will be integrated with health sciences research consisting of clinical observational and intervention studies, health economics and health education to specifically change practice in managing community-acquired LRTI. In the jointly executed research programme, 17 academic groups, spread widely across 9 EU Member States and 5 SMEs will participate. GRACE will organise professional education, including web-based teaching and practical courses, through two leading European scientific societies (European Society of Clinical Microbiology and Infectious Diseases and European Respiratory Society) to disseminate the excellence of the programme. A high level of co-ordination will be obtained through a professionally IT-supported and rigorous management structure. The network will receive €11.5 million from the EU’s 6th Research Framework Programme and will run until at least Behaviour and expectations of doctors and patients? Aetiology? Diagnostic strategies? Prediction of poor outcome? Treatment? Cost-effectiveness? Potential of genetics to enhance clinical care? GAPS IN KNOWLEDGE ON CA-LRTI